Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, QurAlis is raising $60,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kasper Roet played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms. The QurAlis strategy is to attack ALS one gene at a time by using a transformative system in which cells from ALS patients are used to model the disease in the lab to identify new drugs. QurAlis cofounders Kevin Eggan and Clifford Woolf, both Harvard professors, have pioneered this discovery technology for ALS, which has produced one drug candidate, Ezogabine, now under investigation in a phase 2 clinical trial.

To learn more about QurAlis, visit http://quralis.com/

Contact:
Kasper Roet, Chief Executive Officer
781-816-7031
https://www.linkedin.com/in/kasper-roet-9817395/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved